1.
Bioorg Med Chem Lett
; 8(19): 2635-40, 1998 Oct 06.
Artigo
em Inglês
| MEDLINE
| ID: mdl-9873594
RESUMO
A series of novel selective phosphodiesterase 4 (PDE4) inhibitors has been developed which displays activity both in vitro and in vivo. These compounds possess good selectivity for the catalytic site of PDE4 over the high affinity Rolipram binding site. In vivo studies demonstrate a reduced propensity to display the emetic side effects which are commonly observed with PDE4 inhibitors.